Wednesday, August 22, 2012

Lipitor U.S. Sales Tank 70% in 2012 vs 2011!

According to Drugs.com, Lipitor U.S. sales in Q2 of 2012 were only 30% of what they were in Q2 2011 ($579 million vs. $1,949 million, respectively (see chart below; Source: http://www.drugs.com/stats/lipitor).


Meanwhile, sales of Crestor (a competitor anti-cholesterol drug) increased only somewhat during the same period (see chart below; Source: http://www.drugs.com/stats/crestor).


I conclude that most of the loss of Lipitor sales was due to direct competition from generic versions of Lipitor now currently available, which is further proof that Pfizer's "innovative" attempts to stem the generic Lipitor tide has failed (see also "Pfizer Throws In the Lipitor Marketing Towel").

3 comments:

  1. Anonymous7:30 AM

    Failed? 70% erosion after 1 year sounds like a success to me, but maybe I am a "glass half full" type of person.

    ReplyDelete
    Replies
    1. It's not a matter of glass half full or half empty; it's a matter of the goal that Pfizer set. Considering that Pfizer's goal was on maintaining a 40% share of the combined market for Lipitor and its generic equivalents for at least 6 months after generic brands are launched, yes, I think it's plan failed. See http://bit.ly/PzmZxD

      Delete
    2. Anonymous6:38 AM

      Well that does sound like a lofty goal.

      Interestingly, the IMS data you reference give Lipitor a 47% share of the atorvastatin market in Q1 and 42% in Q2, if you are measuring by value.

      Delete